Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Michelino De LaurentiisSimona BorstnarMario CamponeEllen WarnerJavier Salvador BofillWilliam JacotSusan DentMiguel MartinAlistair RingPaul CottuJanice LuEva CiruelosHamdy A AzimSanjoy ChatterjeeKatie ZhouJiwen WuLakshmi Menon-SinghClaudio ZamagniPublished in: Breast cancer research and treatment (2021)
linicalTrials.gov NCT02941926.